Patents Assigned to Shire-NPS Pharmaceuticals, Inc.
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9968657
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9968658
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9649365
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 16, 2017
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9603901
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 28, 2017
    Assignee: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9603902
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 28, 2017
    Assignee: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9603903
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 28, 2017
    Assignee: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9597373
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 21, 2017
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9592274
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 14, 2017
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9592273
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 14, 2017
    Assignee: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9572867
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: February 21, 2017
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch